Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Dr Dorff on a Real-World Study of Relugolix in Advanced Prostate Cancer

May 13th 2025

Tanya B. Dorff, MD, discusses the clinical characteristics and treatment preferences for initiating relugolix during prostate cancer treatment

Dr Hong on the FDA Approval of Larotrectinib for NTRK+ Solid Tumors

May 13th 2025

David S. Hong, MD, discusses the FDA’s full approval of larotrectinib for patients with solid tumors harboring an NTRK gene fusion.

Dr Chiappori on the Role of Ensartinib for ALK+ NSCLC With CNS Metastases

May 13th 2025

Alberto Chiappori, MD, discusses the inclusion of patients with CNS metastases in the eXALT3 trial of ensartinib in ALK-positive NSCLC.

Dr Tarantino on the Expanding Role of T-DXd in HER2+ Breast Cancer

May 13th 2025

Paolo Tarantino, MD, discusses the expanding role of T-DXd in HER2-positive breast cancer.

Frontline Belrestotug Plus Dostarlimab Misses PFS End Point in PD-L1–High NSCLC

May 13th 2025

Belrestotug plus dostarlimab did not improve PFS vs dostarlimab monotherapy in PD-L1–high NSCLC, supporting the termination of belrestotug development.

Piflufolastat (18F) Wins Approval in Switzerland for Detecting PSMA+ Lesions in Prostate Cancer

May 13th 2025

Switzerland has approved piflufolastat (18F) as an imaging agent to detect PSMA-positive lesions in prostate cancer.

CX-2051 Demonstrates Preliminary Activity in Heavily Pretreated Advanced Colorectal Cancer

May 13th 2025

CX-2051 elicited an overall response rate of 28% with manageable safety in heavily pretreated colorectal cancer.

Dr Sobh on Ongoing Investigations of NSD2 in Modulating Immune Surveillance in Myeloma

May 12th 2025

Amin Sobh, PhD, discusses ongoing efforts to investigate the role of NSD2 expression in modulating immune surveillance in multiple myeloma.

Dr Garcia on the Effect of the Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in in PSMA+ mCRPC

May 12th 2025

Jorge A. Garcia, MD, discusses the clinical impact of the FDA’s expanded approval of lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mCRPC.

THE001 Receives Orphan Drug Designation for Soft Tissue Sarcoma

May 12th 2025

THE001, a doxorubicin-encapsulating thermosensitive liposome therapy, has been granted FDA orphan drug designation for soft tissue sarcoma.

Novel Agents and Personalized Biomarkers May Propel a New Era of MDS Management

May 12th 2025

Amer Zeidan, MBBS, discusses evolutions in the myelodysplastic syndrome treatment paradigm and ongoing research seeking to improve treatment efficacy.

Frontline Disitamab Vedotin Plus Toripalimab Improves PFS and OS in HER2+ Metastatic Urothelial Carcinoma

May 12th 2025

Disitamab vedotin plus toripalimab improved PFS and OS vs chemotherapy in HER2-expressing metastatic urothelial carcinoma.

Allogeneic CAR T-Cell Therapy CT0596 Yields Preliminary Efficacy and Safety in R/R Myeloma

May 12th 2025

The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.

ADRX-0706 Secures FDA Fast Track Designation for Advanced Squamous Cell Cervical Cancer

May 12th 2025

The FDA granted fast track designation to ADRX-0706 for locally advanced or metastatic squamous cell cervical cancer.

Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025

May 9th 2025

Poll results highlighted key lung cancer abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Patient Symptoms and Disease Features Guide Pirtobrutinib Use in R/R CLL

May 9th 2025

Nicole Lamanna, MD, discusses pirtobrutinib decision-making in the relapsed/refractory CLL setting and ongoing earlier-line research with the agent.

Lifileucel Paves the Way for Evolving Treatment Approaches After PD-1 Inhibition in Advanced Melanoma

May 8th 2025

Justin Moser, MD, discusses efforts to develop a broader range of immunotherapy approaches for advanced melanoma after PD-1 inhibition.

FDA Lifts Clinical Hold on Tabelecleucel Trial for EBV+ Post-Transplant Lymphoproliferative Disease

May 8th 2025

FDA lifts clinical hold on tabelecleucel IND, enabling trial resumption in EBV+ PTLD following HSCT or SOT in relapsed/refractory patients.

Dr Pimenta on Novel Approaches to Evaluate Tumor Progression and Immune Evasion in Soft Tissue Sarcomas

May 7th 2025

Erica Maria Pimenta, MD, PhD, discusses the future for evaluating tumor progression and immune evasion in soft tissue sarcomas.

Dr Kruse on Long-Term Data for Adjuvant Abemaciclib Plus Endocrine Therapy in HR+/ HER2– Early Breast Cancer

May 7th 2025

Megan Kruse, MD, discusses long-term outcomes adjuvant abemaciclib with endocrine therapy in HR-positive, HER2-negative, high-risk early breast cancer.